Allianz
CRL icon

Allianz’s Charles River Laboratories CRL Stock Holding History

Allianz’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$215K Buy
+730
New +$192K ﹤0.01% 372

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $25.4B AUM 35.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

Allianz's CRL Position: Q3 2026 in Review

Allianz opened a new position in Charles River Laboratories (CRL) in Q3 2026: 730 shares worth $215K. The stake represents ﹤0.01% of the portfolio and ranks #372 among its holdings.

432 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Allianz held 730 shares of Charles River Laboratories worth $215K as of Q3 2026.
  • Charles River Laboratories was a new Allianz position in Q3 2026.
  • Charles River Laboratories made up ﹤0.01% of Allianz's portfolio in Q3 2026, its #372 holding.
  • 432 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Allianz's 13F filing for Q3 2026, filed 12 Nov 2026.